MASSDEVICE ON CALL — The market is awash with rumors that technology titan Apple Inc. (NSDQ:AAPL) is building mobile medical devices for future generations of its iPhones and the long rumored iWatch, with latest reports suggesting that the company may have nabbed a former employee of patient monitoring systems maker Masimo (NSDQ:MASI).
O’Reilly was chief medical officer at Masimo from 2008 until just last year, and he still serves on the board of Masimo’s Foundation for Ethics, Innovation & Competition in Healthcare, according to the group’s website.
MobiHealthNews cited an anonymous tipster who told the news source that O’Reilly had joined Apple. His LinkedIn profile notes that his employment with Masimo ended in July 2013, but doesn’t mention any new positions with Apple. O’Reilly hasn’t confirmed the rumors and Masimo has declined to comment on them, but speculations have been rampant amid increased interest in Apple’s potential efforts to build wearable monitoring technology.
Apple has yet to say if or when it will release a so-called "iWatch" or what, exactly, such a device would be capable of, but last month speculation hinged on reports that Apple had nabbed medical sensor experts Nancy Dougherty, formerly involved with transdermal drug delivery devices and wearable vital signs monitoring, and Ravi Narasimhan, who also worked with personal vital sign monitoring.
These latest hires aren’t Apple’s 1st to fit with growing speculation that the company’s building a sensor-laden iWatch. The tech titan last year hired high-level members of C8 MediSensors and Senseonics.
Not all docs are sold on electronic medical records
Despite widespread acceptance and federal incentive programs, a lot of doctors are still shying away from electronic medical records, according to a study released by the Centers for Medicare & Medicaid Services.
iRhythm lands Aetna coverage for new ZIO wearable heart monitor
Health insurer Aetna announced that it will provide coverage for medtech startup iRhythm’s ZIO wearable heart monitoring patch under new "medically necessary" status for evaluating syncope or light-headedness or to document abnormal heart rhythms.
Biotech IPOs keep gaining steam
Early 2014 is poised to break records for biotech initial public offerings, with 2 groups with 14 IPOs planned for a 2-week period spanning the end of January and 1st half of February.